title: Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma.
abstract: OBJECTIVE
  The combination of the antiangiogenic antibody bevacizumab with standard chemotherapy has improved the prognosis in patients with metastastic colorectal cancer and other advanced cancers. The role of combined anti-VEGF and chemotherapy in metastastic melanoma is just starting to be elucidated.
  
  
  METHODS
  We tested this notion in three patients with advanced and therapy-refractory melanoma.
  
  
  RESULTS
  Interestingly, two patients achieved objective regressions after three courses of therapy; the third patient, albeit progressing demonstrated a pronounced liquid necrosis in bulky lymphnode metastasis.
  
  
  CONCLUSIONS
  Further studies are warranted to scrutinize these impressive therapeutic effects on the combination of bevacizumab and chemotherapy in melanoma.
authors.forename: Patrick
authors.initials: P
authors.lastname: Terheyden
authors.forename: Maja Ann
authors.initials: MA
authors.lastname: Hofmann
authors.forename: M
authors.initials: M
authors.lastname: Weininger
authors.forename: Eva-B
authors.initials: EB
authors.lastname: Bröcker
authors.forename: Jürgen C
authors.initials: JC
authors.lastname: Becker
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab